Moreover, DEX administration at a dose of 100 nmol/L significantly decreased expression of CSPG CD44 in GR-positive bladder cancer cells both in mRNA (by 69.7%, p < 0.05) and protein levels 48 h after the treatment, although GR silencing in these cells had the opposite effects [81]. This evidence concerns the gene NR3C1 and urinary bladder cancer.